Buy Rating Justified for Sensorion SAS Amid Promising Clinical Developments and Recruitment Momentum
Sensorion SAS (RFM – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Clémence ...
Impacts2d
Sensorion Unveils Half-Year 2024 Report
Sensorion has announced the availability of its half-year 2024 report. Takeaway Points Sensorion Unveils Half-Year 2024 ...
Sensorion Reports New Positive Clinical Results Presented at the World Congress of Audiology
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing ...
Sensorion Announces the Availability of its Half Year 2024 Report
Sensorion (FR0012596468 – ALSEN), a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat, and prevent within the field of hearing ...
precisionmedicineonline2d
Sensorion Doses First Patient in Phase I/II Trial of OTOF-Linked Hearing Loss Gene Therapy
Montpellier, France-based Sensorion is enrolling three patients between six and 31 months of age in each of the two cohorts in the Audiogene trial. Patients will receive one of two doses of an ...
Buy Rating Affirmed for Sensorion SAS on Promising Auditory Treatment Advances
In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Sensorion SAS (RFM – Research Report), with ...
Sensorion Announces New Positive Clinical Data Across its Gene Therapy and Small Molecule Programs at the World Congress of Audiology in Paris
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing ...